History of peptic ulcer, hematemesis, melena, bleeding diathesis or w/ severe hepatic or renal insufficiency. Discontinue use if abnormal liver function tests persist or worsen, clinical signs & symptoms consistent w/ liver disease develop or eosinophilia, rash occur. Hepatic porphyria. Increased risk of serious CV thrombotic events (MI & stroke) in high dose or long-term treatment. Periodically re-evaluate patient's need for symptomatic relief & response to therapy especially when treatment continues for >4 wk. Remain alert for sign & symptoms of serious arteriothrombotic events (eg, chest pain, shortness of breath, weakness, slurring of speech). Pregnancy.